Sanofi ROA 2010-2023 | SNY
Current and historical return on assets (ROA) values for Sanofi (SNY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Sanofi ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2023-12-31 |
$5.84B |
$136.87B |
8.55% |
| 2023-09-30 |
$9.68B |
$0.00B |
14.33% |
| 2023-06-30 |
$9.02B |
$136.69B |
13.35% |
| 2023-03-31 |
$8.71B |
$0.00B |
13.23% |
| 2022-12-31 |
$8.82B |
$133.51B |
13.41% |
| 2022-09-30 |
$8.33B |
$0.00B |
25.69% |
| 2022-03-31 |
$6.88B |
$0.00B |
20.32% |
| 2021-09-30 |
$6.90B |
$0.00B |
20.40% |
| 2021-03-31 |
$7.99B |
$0.00B |
inf% |
| 2020-09-30 |
$7.39B |
$0.00B |
inf% |
| 2020-03-31 |
$6.36B |
$0.00B |
inf% |
| 2019-09-30 |
$4.98B |
$0.00B |
17.65% |
| 2019-03-31 |
$4.86B |
$0.00B |
17.22% |
| 2018-03-31 |
$4.71B |
$0.00B |
8.37% |
| 2017-12-31 |
$9.53B |
$112.83B |
16.96% |
| 2017-09-30 |
$9.90B |
$0.00B |
17.37% |
| 2017-06-30 |
$9.92B |
$112.08B |
17.41% |
| 2017-03-31 |
$10.09B |
$0.00B |
17.71% |
| 2016-12-31 |
$5.21B |
$115.83B |
9.15% |
| 2016-09-30 |
$6.19B |
$0.00B |
22.10% |
| 2016-06-30 |
$5.76B |
$111.96B |
10.46% |
| 2016-03-31 |
$5.52B |
$0.00B |
9.48% |
| 2015-09-30 |
$4.90B |
$0.00B |
5.45% |
| 2015-06-30 |
$4.59B |
$108.32B |
3.75% |
| 2014-06-30 |
$5.57B |
$124.45B |
5.83% |
| 2013-06-30 |
$6.39B |
$126.66B |
6.44% |
| 2012-06-30 |
$8.61B |
$130.75B |
12.74% |
| 2012-03-31 |
$8.56B |
$0.00B |
12.10% |
| 2011-12-31 |
$9.33B |
$139.51B |
13.20% |
| 2011-09-30 |
$8.04B |
$0.00B |
12.53% |
| 2011-06-30 |
$7.45B |
$143.31B |
11.62% |
| 2011-03-31 |
$8.22B |
$0.00B |
14.73% |
| 2010-12-31 |
$8.24B |
$113.22B |
14.76% |
| 2010-09-30 |
$9.30B |
$0.00B |
16.78% |
| 2010-06-30 |
$10.37B |
$110.06B |
18.71% |
| 2010-03-31 |
$11.38B |
$0.00B |
21.05% |
| 2009-12-31 |
$10.99B |
$111.64B |
20.34% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$117.905B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
